Spots Global Cancer Trial Database for Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma
Official Title: An Open-Label, Dose Escalation/Dose Exploration, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single/Multiple Infusion of CT0181 Injection in Patients With Advanced Hepatocellular Carcinoma
Study ID: NCT04973098
Conditions
Interventions
Study Description
Brief Summary: A Phase I Clinical Study of CT0181 cells in Patients with Advanced Hepatocellular Carcinoma
Detailed Description: Primary objectives: Evaluate the safety and tolerance of CT0181 cells in patients with advanced hepatocellular carcinoma within 28 days after the first infusion Secondary objectives: Evaluate the metabolic kinetics of CT0181 cells ; Evaluate overall safety and tolerability ; Evaluate the initial efficacy of CT0181 cell infusion in the treatment of advanced hepatocellular carcinoma with positive Glypican-3（GPC3 ）expression.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Peking University, Beijing, Beijing, China
Contact Details
Name: Lin Shen
Affiliation: Peking University Cancer Hospital & Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
